SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025 . The presentation will include Phase 2b results on the primary and secondary endpoints from the 16-week induction phase of the... Read More

SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025 . H.C. Wainwright 27 th Annual Global Investment Conference on Wednesday,... Read More

SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025 . Cash and investments in marketable securities on June 30, 2025 were $175.9 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities at June 30, 2025 do not include $107.5 million of approximate net proceeds from the secondary... Read More

SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific Time . This press release and live audio-only... Read More

SAN FRANCISCO , July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms. Rezpegaldesleukin is an investigational biologic therapy that targets... Read More

SAN FRANCISCO , July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $115 million of shares of its common stock. Nektar sold 4,893,618 shares of common stock in the offering, which includes 638,298 shares sold upon exercise in... Read More

SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a... Read More

SAN FRANCISCO , June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the... Read More

Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA Rapid onset of EASI reduction and magnitude of itch improvement show potential differentiation of this novel... Read More

SAN FRANCISCO , June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg)... Read More

SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025 : H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025 – webcast to be available at 1:30 p.m. Eastern Time /... Read More

SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025 . Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth... Read More

SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . This press release and live audio-only webcast... Read More

SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link here The... Read More

SAN FRANCISCO , March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024 . Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the... Read More

SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . This... Read More

SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune... Read More

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study SAN FRANCISCO and NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).... Read More

SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST . Nektar's Chief Research & Development Officer, Jonathan Zalevsky , Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr.... Read More

SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are... Read More

SAN FRANCISCO , Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical... Read More

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN FRANCISCO , Dec. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study... Read More

NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions SAN FRANCISCO , Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in Washington, D.C. from November 14-19, 2024 . NKTR-422 is a... Read More

SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024 . Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the... Read More

NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas... Read More

SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here Piper Sandler 36 th Annual Healthcare Conference in New York, NY on Wednesday,... Read More

Huntsville -based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 million equity ownership in new portfolio company. Strategic divestiture allows Nektar to streamline its operations and continue its strategic focus on the development of core R&D programs in immunology. SAN FRANCISCO , Nov. 4,... Read More

SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press release and live... Read More

Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials SAN... Read More

Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) Eight of nine patients achieved complete remission, all without detectable MRD SAN FRANCISCO , Oct. 17, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with... Read More

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis SAN FRANCISCO , Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV)... Read More

SAN FRANCISCO , Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference in New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m.... Read More

SAN FRANCISCO , Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024 . Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter... Read More

SAN FRANCISCO , Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press release and live audio-only... Read More

NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 SAN FRANCISCO , June 12, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for... Read More

SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time The... Read More

SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter... Read More

SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press release and live audio-only... Read More

SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2 nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time . The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar... Read More

SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata. Rezpegaldesleukin (REZPEG) is a novel agonistic T regulatory cell biologic that is designed to both dampen the... Read More

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023 . Cash and investments in marketable securities at December 31, 2023 , were $329.4 million as compared to $505.0 million at December 31, 2022 . Nektar's cash and marketable securities are expected to support strategic development activities and... Read More

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the "PIPE") for gross proceeds of $30 million , before deducting expenses. In the... Read More

SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44 th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time . The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website:... Read More

SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press... Read More

SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website:... Read More

NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65 th American Society of Hematology (ASH) Annual Meeting demonstrating that... Read More

SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023 . Cash and investments in marketable securities at September 30, 2023 , were $372.7 million as compared to $505.0 million at December 31, 2022 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into the... Read More

SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press release and live audio-only... Read More

Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQI and POEM Endpoints SAN FRANCISCO , Oct. 13 , 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a... Read More

Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO , Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and... Read More

SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG"). The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC)... Read More

New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study New Phase 2a Study Also Being Planned for Rezpegaldesleukin in Alopecia Areata SAN FRANCISCO , Sept. 13, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b... Read More

SAN FRANCISCO , Sept. 6, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m. PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients with atopic dermatitis, the atopic dermatitis treatment landscape, and the potential role of REZPEG, Nektar's novel, first-in-class... Read More

SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023 . Cash and investments in marketable securities at June 30, 2023 , were $409.4 million as compared to $505.0 million at December 31, 2022 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into at least the... Read More

EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 SAN FRANCISCO , Aug. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin (REZPEG) that were presented at the September 2022 EADV Congress... Read More

SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time . The press release and live audio-only... Read More

SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20 p.m. Pacific Time . The presentation will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website:... Read More

SAN FRANCISCO , May 9, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023 . Cash and investments in marketable securities at March 31, 2023 , were $456.8 million as compared to $505.0 million at December 31, 2022 . Nektar's cash and marketable securities are expected to support strategic development activities and operations into at least the... Read More

Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis SAN FRANCISCO , April 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company. As announced in a press release issued on April 17 , Nektar plans to move forward with REZPEG and will initiate a Phase 2b study in patients with moderate-to-severe... Read More

Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to continue as strategic partnering options are pursued Cost restructuring plan reduces San Francisco -based workforce by approximately 60% and extends cash runway into the middle of 2026 Company to announce financial results for the first... Read More

SAN FRANCISCO , March 11, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or securities at Silicon Valley Bank. At December 31, 2022 , the company had approximately $505 million in cash and investments in marketable securities. About Nektar Therapeutics Nektar Therapeutics is a... Read More

SAN FRANCISCO , Feb. 28, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022 . Cash and investments in marketable securities at December 31, 2022 , were approximately $505.0 million as compared to $798.8 million at December 31, 2021 . "We are committed to ensuring that our existing cash can support a runway through at least the... Read More

Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful improvements observed as compared to placebo across secondary endpoints including BICLA and LLDAS at the mid-dose level in the study Nektar and Lilly are discussing next steps for trials planned in other indications SAN FRANCISCO , Feb. 23, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)... Read More

SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time . The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of... Read More

Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma SAN FRANCISCO , Dec. 12, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64 th American Society of Hematology (ASH) Annual Meeting. NKTR-255 is an... Read More

SAN FRANCISCO , Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST . Nektar management will be joined by Dr. Cameron Turtle , Professor and Chair of Cancer Immunotherapy at the University of Sydney, Australia and Fred Hutchinson Cancer Center affiliate, to discuss the NKTR-255 program and the potential... Read More